循環性ユーモラル因子と内皮原始細胞は,異なる冠動脈の付随サポートを持つ患者の間で異なる
Pier D Lambiase1, Richard J Edwards, Prodromos Anthopoulos
1Department of Cardiology, GKT School of Medicine, The Rayne Institute, St Thomas' Hospital, London, UK.
Circulation
|June 9, 2004
まとめ
循環中の内皮原生細胞 (EPC) の減少は,冠動脈動脈疾患の患者における冠動脈副次細胞の発達不良に関連しています. EPCを増やすことは,担保の形成を強化する可能性があります.
科学分野:
- 心血管研究 循環器科の研究
- アンジオゲネシス (血管新生)
- 血管生物学 血管生物学
背景:
- 同様の冠動脈疾患のパターンを有する患者の変異性冠動脈の付随形成のメカニズムは完全に理解されていません.
- この研究では,この変異における循環する体調および細胞因子の役割を調査しています.
研究 の 目的:
- 循環系因子と冠動脈の副産物発達の関連性を調査する.
- 減少した内皮原生細胞 (EPC) または変化した成長因子の活性が不十分な担保に寄与するかどうかを判断する.
主な方法:
- 隔離された左前側下降冠動脈疾患の30人の患者で評価された付随流量指数 (CFI). 経皮冠動脈介入後の冠動脈疾患.
- 冠動脈シナスの成長因子,プラズマの血管新生およびミトゲン活性,循環中のCD34/CD133陽性血液形成前駆体細胞および微分化されたEPCを測定した.
主要な成果:
- 補償が不十分な患者 (CFI <0.25) は,成長因子の濃度が低く,プラズマにおける血管新生性効果が弱かった.
- 循環中の血液形成前駆体細胞とCFI (r=0.75,P<0.001) の間には強い正の相関が認められた.
- 差異化されたEPCの数が著しく減少したのは,不十分な補償 (75%の循環減少,70%の培養) を受けた患者で観察された.
結論:
- 不十分な冠動脈の付随的発達は,循環中のEPCの減少と,化学的/血管新生性の活動障害と関連しています.
- 発見は,循環中のEPCを増加させ,冠動脈の付随形成を促進することを目的とした治療戦略を支持する.
さらに関連する動画
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
4.9K
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
2.8K
関連する概念動画
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Regulation of Hematopoietic Stem Cells
3.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.5K
Role of Hematopoietic Growth Factors
3.9K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
3.9K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
